Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LOQTORZI safely and effectively. See full prescribing information for LOQTORZI. LOQTORZI® (toripalimab-tpzi) injection, for intravenous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). LOQTORZI is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
- generic_name
- toripalimab-tpzi
- product_names
- toripalimab-tpzi
- ndc
- 70114-340, 70114-340-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en